ticlopidine has been researched along with Deep Vein Thrombosis in 38 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Warfarin treatment within 12 months achieved significantly higher rates of complete recanalization than aspirin or clopidogrel in patients with PVT (54." | 5.48 | Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes. ( Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, LH; Yue-Meng, W, 2018) |
| "Stasis ulcers are commonly the result of chronic venous insufficiency." | 5.31 | Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report. ( Bick, RL; Scott, RG, 2001) |
| "Based on the established fact that anticoagulation with warfarin is superior to antiplatelet agents in the prevention of thromboembolic events in atrial fibrillation (AF), we propose that, in contrast to atherothrombotic disorders, the risk of developing a stroke or thromboembolic event in AF is more likely to be affected by the coagulation pathway than by platelet activity." | 4.82 | Atrial fibrillation: should we target platelets or the coagulation pathway? ( Lip, GY; Tan, KT, 2003) |
| "To compare venous thrombosis rates among animals treated with aspirin, clopidogrel bisulfate, and ketorolac tromethamine using an anastomotic "tuck" model." | 3.77 | Effects of antithrombogenic agents on microvenous anastomoses in a rat model. ( Harsha, WJ; Hayden, RE; Kau, RL; Kim, N, 2011) |
| "The antithrombotic effect of Danggui and Honghua, herbs commonly used in Traditional Chinese medicine to treat the syndrome corresponding to vascular thrombosis, and their potential interactions with clopidogrel were investigated." | 3.76 | Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel. ( Li, Y; Wang, N, 2010) |
| "Thrombosis is of greater overall clinical importance in terms of morbidity and mortality than all of the hemorrhagic disorders combined." | 2.41 | Antithrombotic agents: implications in dentistry. ( Henry, RG; Little, JW; McIntosh, BA; Miller, CS, 2002) |
| "Warfarin treatment within 12 months achieved significantly higher rates of complete recanalization than aspirin or clopidogrel in patients with PVT (54." | 1.48 | Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes. ( Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, LH; Yue-Meng, W, 2018) |
| "Thulium VapoEnucleation of the prostate seems to be a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk on OA." | 1.40 | Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. ( Bach, T; Brüning, M; Gabuev, A; Gross, AJ; Herrmann, TR; Netsch, C; Stoehrer, M, 2014) |
| "Intrahepatic hemorrhage is a very rare complication of warfarin, and our patient experienced intrahepatic and subgaleal hemorrhage although she did not have any risk factors for bleeding or instability of the international normalized ratio control." | 1.39 | Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy. ( Baek, YH; Cho, DS; Chung, WT; Han, SY; Kang, SH; Lee, SW; Park, IC, 2013) |
| "Clinically symptomatic deep venous thrombosis was detected in association with four (0." | 1.34 | Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. ( Boutary, M; Dorr, LD; Gendelman, V; Long, WT; Maheshwari, AV; Wan, Z, 2007) |
| "Early administration of a combined regimen of clopidogrel and aspirin following off-pump CABG is safe and is associated with a relatively low incidence of major adverse cardiac events, bleeding, PE, and DVT." | 1.32 | A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting. ( Benhameid, O; Endo, M; Shennib, H, 2003) |
| "Stasis ulcers are commonly the result of chronic venous insufficiency." | 1.31 | Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report. ( Bick, RL; Scott, RG, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.63) | 18.2507 |
| 2000's | 22 (57.89) | 29.6817 |
| 2010's | 15 (39.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wan, YM | 1 |
| Li, YH | 2 |
| Wu, HM | 2 |
| Xu, ZY | 1 |
| Xu, Y | 2 |
| Yang, LH | 2 |
| Wu, XN | 1 |
| Yang, JH | 1 |
| Belcaro, G | 1 |
| Dugall, M | 1 |
| Hu, S | 1 |
| Feragalli, B | 1 |
| Cotellese, R | 1 |
| Ledda, A | 1 |
| Corsi, M | 1 |
| Ricci, A | 1 |
| Ippolito, E | 1 |
| Errichi, BM | 1 |
| Cornelli, U | 1 |
| Cesarone, MR | 1 |
| Hosoi, M | 1 |
| Cooley, BC | 2 |
| Herrera, AJ | 1 |
| Netsch, C | 1 |
| Stoehrer, M | 1 |
| Brüning, M | 1 |
| Gabuev, A | 1 |
| Bach, T | 1 |
| Herrmann, TR | 1 |
| Gross, AJ | 1 |
| Park, IC | 1 |
| Baek, YH | 1 |
| Han, SY | 1 |
| Lee, SW | 2 |
| Chung, WT | 1 |
| Kang, SH | 1 |
| Cho, DS | 1 |
| Lawall, H | 1 |
| Oberacker, R | 1 |
| Zemmrich, C | 1 |
| Bramlage, P | 1 |
| Diehm, C | 1 |
| Schellong, SM | 1 |
| Gavrilenko, AV | 1 |
| Voronov, DA | 1 |
| Damanti, S | 1 |
| Artoni, A | 1 |
| Lucchi, T | 1 |
| Mannucci, PM | 1 |
| Mari, D | 1 |
| Bergamaschini, L | 1 |
| Windecker, S | 1 |
| Tijssen, J | 1 |
| Giustino, G | 1 |
| Guimarães, AH | 1 |
| Mehran, R | 1 |
| Valgimigli, M | 1 |
| Vranckx, P | 1 |
| Welsh, RC | 1 |
| Baber, U | 1 |
| van Es, GA | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Dangas, GD | 1 |
| Yue-Meng, W | 1 |
| Yang, J | 1 |
| Lijnen, HR | 1 |
| Helsen, S | 1 |
| Hoylaerts, MF | 1 |
| Li, Y | 1 |
| Wang, N | 1 |
| Scacciatella, P | 1 |
| Butera, G | 1 |
| Amato, G | 1 |
| Tomassini, F | 1 |
| Giorgi, M | 1 |
| Marra, S | 1 |
| Naik, A | 1 |
| Mian, T | 1 |
| Abraham, A | 1 |
| Rajput, V | 1 |
| Harsha, WJ | 1 |
| Kau, RL | 1 |
| Kim, N | 1 |
| Hayden, RE | 1 |
| Alam, M | 1 |
| Goldberg, LH | 1 |
| Hankey, GJ | 1 |
| Eikelboom, JW | 1 |
| Jessup, DB | 1 |
| Coletti, AT | 1 |
| Muhlestein, JB | 1 |
| Barry, WH | 1 |
| Shean, FC | 1 |
| Whisenant, BK | 1 |
| Igaki, N | 1 |
| Matsuda, T | 1 |
| Yatani, H | 1 |
| Kawaguchi, T | 1 |
| Kida, A | 1 |
| Yanase, K | 1 |
| Moriguchi, R | 1 |
| Sakai, M | 1 |
| Tamada, F | 1 |
| Goto, T | 1 |
| Shennib, H | 1 |
| Endo, M | 1 |
| Benhameid, O | 1 |
| Di Micco, B | 1 |
| Di Micco, G | 1 |
| Niglio, A | 1 |
| Romano, M | 1 |
| Di Micco, P | 1 |
| Tan, KT | 1 |
| Lip, GY | 1 |
| Cattaneo, M | 1 |
| Sick, PB | 1 |
| Brosteanu, O | 1 |
| Ulrich, M | 1 |
| Thiele, H | 1 |
| Niebauer, J | 1 |
| Busch, I | 1 |
| Schuler, G | 1 |
| Meyer Samama, M | 1 |
| Hitos, K | 1 |
| Fletcher, JP | 1 |
| Helft, G | 1 |
| Gilard, M | 1 |
| Le Feuvre, C | 1 |
| Zaman, AG | 1 |
| Zimarino, M | 1 |
| Renda, G | 1 |
| De Caterina, R | 1 |
| Dorr, LD | 1 |
| Gendelman, V | 1 |
| Maheshwari, AV | 1 |
| Boutary, M | 1 |
| Wan, Z | 1 |
| Long, WT | 1 |
| McBane, RD | 1 |
| Leadley, RJ | 1 |
| Baxi, SM | 1 |
| Karnicki, K | 1 |
| Wysokinski, W | 1 |
| Katz, MG | 1 |
| Shimonov, M | 1 |
| Elias, S | 1 |
| Ben Eli, M | 1 |
| Hauptman, E | 1 |
| Sasson, L | 1 |
| Landolfi, R | 1 |
| Di Gennaro, L | 1 |
| Morishita, K | 1 |
| Iwamoto, M | 1 |
| Frangos, SG | 1 |
| Chen, AH | 1 |
| Sumpio, B | 1 |
| Bick, RL | 1 |
| Scott, RG | 1 |
| Tufano, A | 1 |
| Cerbone, AM | 1 |
| Di Minno, G | 1 |
| Little, JW | 1 |
| Miller, CS | 1 |
| Henry, RG | 1 |
| McIntosh, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| [NCT00000614] | Phase 3 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
8 reviews available for ticlopidine and Deep Vein Thrombosis
| Article | Year |
|---|---|
Economy class syndrome complicated by stroke: a rare condition due to paradoxical embolism--a case report and review of the literature.
Topics: Aircraft; Anticoagulants; Aspirin; Clopidogrel; Echocardiography; Embolism, Paradoxical; Foramen Ova | 2011 |
Atrial fibrillation: should we target platelets or the coagulation pathway?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Assessment; | 2003 |
Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance.
Topics: Aspirin; Clopidogrel; Drug Resistance; Humans; Ticlopidine; Treatment Failure; Treatment Outcome; Ve | 2004 |
[The new antithrombotic agents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylami | 2005 |
Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Admi | 2006 |
Vascular drugs in the new millennium.
Topics: Abciximab; Animals; Anistreplase; Antibodies, Monoclonal; Anticoagulants; Aspirin; Chondroitin Sulfa | 2000 |
The use of antithrombotic drugs in older people.
Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myo | 2002 |
Antithrombotic agents: implications in dentistry.
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Dental Care; Drug Interactions; Embol | 2002 |
3 trials available for ticlopidine and Deep Vein Thrombosis
| Article | Year |
|---|---|
[Possibilities and results of using clopidogrel (Listab) in comprehensive treatment of patients with crural deep veins thrombosis].
Topics: Adult; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leg; | 2015 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl | 2005 |
27 other studies available for ticlopidine and Deep Vein Thrombosis
| Article | Year |
|---|---|
Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement: An observational study (STROBE compliant).
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Female; Humans; Leukocyte Coun | 2017 |
Prevention of recurrent venous thrombosis and post-thrombotic syndrome.
Topics: Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; Flavonoids; Glycosaminoglycans; Hum | 2018 |
Cross-modulatory effects of clopidogrel and heparin on platelet and fibrin incorporation in thrombosis.
Topics: Animals; Anticoagulants; Blood Coagulation; Blood Platelets; Clopidogrel; Disease Models, Animal; Dr | 2013 |
Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Hemorrhage; Humans; Incidence; Mal | 2014 |
Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Chemical and Drug Induced Liver Injury; Clopi | 2013 |
Prevalence of deep vein thrombosis in acutely admitted ambulatory non-surgical intensive care unit patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; APACHE; Aspirin; Clopidogrel; Female; Fibrin Fibrinogen Deg | 2014 |
A thrombotic storm.
Topics: Aged; Alprazolam; Amines; Amputation, Surgical; Atorvastatin; Cyclohexanecarboxylic Acids; Female; G | 2017 |
Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Elective Surgical Procedures; Female; Fibrosis | 2018 |
Antithrombotic effect of clopidogrel in a vena cava thrombosis model in obese mice.
Topics: Animals; Clopidogrel; Dietary Fats; Disease Models, Animal; Fibrinolytic Agents; Mice; Mice, Obese; | 2009 |
Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel.
Topics: Animals; Bleeding Time; Carthamus tinctorius; Clopidogrel; Drug Interactions; Drugs, Chinese Herbal; | 2010 |
Iliac vein compression syndrome: an underdiagnosed cause of lower extremity deep venous thrombosis.
Topics: Anticoagulants; Clopidogrel; Constriction, Pathologic; Heparin; Humans; Iliac Vein; Lower Extremity; | 2010 |
Effects of antithrombogenic agents on microvenous anastomoses in a rat model.
Topics: Anastomosis, Surgical; Animals; Aspirin; Clopidogrel; Femoral Vein; Ketorolac Tromethamine; Microcir | 2011 |
Collagen-induced thrombosis in murine arteries and veins.
Topics: Animals; Arterial Occlusive Diseases; Blood Coagulation; Blood Platelets; Carotid Arteries; Clopidog | 2013 |
Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy.
Topics: Aged; Anticoagulants; Aspirin; Carcinoma, Basal Cell; Clopidogrel; Drug Administration Schedule; Fem | 2002 |
Antiplatelet drugs.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2003 |
Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Atrial Fibrillation; Cardia | 2003 |
Deep venous thrombosis, myocardial infarction, and occlusion of vascular access associated with heparin-induced thrombocytopenia in a diabetic hemodialysis patient.
Topics: Anticoagulants; Catheters, Indwelling; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fi | 2003 |
A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Feasibility | 2003 |
Proximal deep venous thrombosis occurring after sudden clopidogrel suspension.
Topics: Aged; Atrial Fibrillation; Clopidogrel; Humans; Male; Platelet Aggregation Inhibitors; Prognosis; Su | 2004 |
Venous thromboembolism and fractured neck of femur.
Topics: Aged; Aged, 80 and over; Anesthesia; Anticoagulants; Aspirin; Blood Loss, Surgical; Blood Transfusio | 2005 |
Triple antithrombotic therapy with aspirin, clopidogrel and warfarin--a persisting dilemma.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Fibrinoly | 2007 |
Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2007 |
Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct Factor Xa inhibitor, compared with antiplatelet agents in pigs.
Topics: Administration, Oral; Angioplasty; Animals; Antithrombin III; Aspirin; Clopidogrel; Constriction, Pa | 2008 |
Portal vein thrombosis associated with coronary artery bypass surgery.
Topics: Aged; Aspirin; Bacteremia; Clopidogrel; Coagulase; Coronary Artery Bypass; Esophageal and Gastric Va | 2008 |
Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; | 2008 |
Synergistic antithrombotic effects of argatroban and ticlopidine in the rat venous thrombosis model.
Topics: Animals; Anticoagulants; Antithrombins; Arginine; Drug Synergism; Male; Pipecolic Acids; Rats; Rats, | 1998 |
Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antiphospholipid Syndrome; Clopidogrel; Dalteparin; | 2001 |